GHK-Cu

GHK-Cu acts through multiple, interacting mechanisms that reflect both its peptide structure and its bound copper ion. The peptide stabilizes copper(II) in a redox-active but tightly chelated form, allowing controlled participation of the metal in cellular processes that depend on copper-containing enzymes, including lysyl oxidase, superoxide dismutase, and cytochrome c oxidase. Delivery of copper to lysyl oxidase has been invoked to explain observations of increased collagen and elastin cross-linking in connective-tissue research models.

At the transcriptional level, exposure of cultured human cells to GHK-Cu has been reported to modulate the expression of large gene sets associated with tissue remodeling, DNA damage response, antioxidant defense, and inflammation. Reports have described upregulation of decorin and certain matrix metalloproteinases together with parallel changes in their tissue inhibitors, generating a net remodeling phenotype favorable to wound resolution in preclinical paradigms. The complex has also been observed to enhance superoxide dismutase activity and reduce iron-driven oxidative damage in tissue homogenates, consistent with antioxidant activity. Receptor-level targets for the peptide itself remain incompletely defined, and current models emphasize the combined effects of controlled copper delivery and peptide-mediated signaling rather than engagement of a single canonical receptor.

The history of GHK begins in 1973, when Loren Pickart, working as a graduate student, isolated a low-molecular-weight factor from human plasma that altered the metabolic phenotype of cultured hepatocytes derived from older donors. The active component was identified as the tripeptide glycyl-histidyl-lysine. Subsequent work in the 1970s and 1980s established that the biologically relevant species under physiological conditions is the copper-bound form, GHK-Cu, and characterized its concentration in plasma and its decline with age.

Through the 1980s and 1990s, dermatological and wound-healing research with GHK-Cu expanded substantially. Reports appeared on the acceleration of skin wound healing in rodent and porcine models, on the stimulation of collagen and glycosaminoglycan synthesis in cultured fibroblasts, and on the modulation of hair follicle biology. Maquart, Wegrowski, Borel and colleagues in France contributed influential mechanistic studies on extracellular matrix synthesis and on the interaction of the complex with copper-dependent enzymes. The molecule entered cosmetic dermatology in this period and has remained a fixture of topical anti-aging formulations.

Through the 2000s and 2010s, mechanistic work expanded into transcriptomic profiling, with reports from Pickart, Margolina, and collaborators describing broad modulation of gene-expression programs associated with tissue remodeling, antioxidant defense, and DNA repair in human cell lines exposed to GHK-Cu. Investigators also examined the complex in models of pulmonary fibrosis, neuropathy, and chronic obstructive pulmonary disease using connectivity-map style analyses of gene-expression signatures. Although controlled clinical trials in humans remain limited compared with the volume of preclinical and cosmetic literature, GHK-Cu continues to attract academic interest as a tractable probe of copper-peptide chemistry and of matrix-biology signaling.